CN115698007A - 一种shp2抑制剂的晶型及其组合物、制备方法和用途 - Google Patents

一种shp2抑制剂的晶型及其组合物、制备方法和用途 Download PDF

Info

Publication number
CN115698007A
CN115698007A CN202180043362.7A CN202180043362A CN115698007A CN 115698007 A CN115698007 A CN 115698007A CN 202180043362 A CN202180043362 A CN 202180043362A CN 115698007 A CN115698007 A CN 115698007A
Authority
CN
China
Prior art keywords
compound
xrpd pattern
peaks
certain embodiments
another example
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043362.7A
Other languages
English (en)
Chinese (zh)
Inventor
郑乾刚
诸葛浩
赵晔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yituo Pharmaceutical Technology Co ltd
Original Assignee
Shanghai Yituo Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yituo Pharmaceutical Technology Co ltd filed Critical Shanghai Yituo Pharmaceutical Technology Co ltd
Publication of CN115698007A publication Critical patent/CN115698007A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180043362.7A 2020-06-18 2021-06-17 一种shp2抑制剂的晶型及其组合物、制备方法和用途 Pending CN115698007A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020096778 2020-06-18
CNPCT/CN2020/096778 2020-06-18
PCT/CN2021/100673 WO2021254449A1 (zh) 2020-06-18 2021-06-17 一种shp2抑制剂的晶型及其组合物、制备方法和用途

Publications (1)

Publication Number Publication Date
CN115698007A true CN115698007A (zh) 2023-02-03

Family

ID=79268476

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043362.7A Pending CN115698007A (zh) 2020-06-18 2021-06-17 一种shp2抑制剂的晶型及其组合物、制备方法和用途

Country Status (8)

Country Link
US (1) US20230339975A1 (cg-RX-API-DMAC7.html)
EP (1) EP4169920A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023532217A (cg-RX-API-DMAC7.html)
KR (1) KR20230026458A (cg-RX-API-DMAC7.html)
CN (1) CN115698007A (cg-RX-API-DMAC7.html)
AU (1) AU2021290733A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183063A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021254449A1 (cg-RX-API-DMAC7.html)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020072656A1 (en) * 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020094018A1 (zh) * 2018-11-06 2020-05-14 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
WO2020094104A1 (zh) * 2018-11-07 2020-05-14 如东凌达生物医药科技有限公司 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
WO2020108590A1 (zh) * 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220073521A1 (en) * 2018-11-30 2022-03-10 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
KR20220054285A (ko) * 2019-06-28 2022-05-02 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 피리미딘 5 원 질소 헤테로고리형 유도체, 이의 제조 방법 및 이의 약학적 용도
WO2021088945A1 (zh) * 2019-11-08 2021-05-14 南京圣和药业股份有限公司 作为shp2抑制剂的化合物及其应用
CN113754683A (zh) * 2020-06-05 2021-12-07 上海奕拓医药科技有限责任公司 同位素取代的螺芳环化合物及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020072656A1 (en) * 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020094018A1 (zh) * 2018-11-06 2020-05-14 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
WO2020094104A1 (zh) * 2018-11-07 2020-05-14 如东凌达生物医药科技有限公司 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CN111153901A (zh) * 2018-11-07 2020-05-15 如东凌达生物医药科技有限公司 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
WO2020108590A1 (zh) * 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
KR20230026458A (ko) 2023-02-24
EP4169920A1 (en) 2023-04-26
WO2021254449A1 (zh) 2021-12-23
US20230339975A1 (en) 2023-10-26
CA3183063A1 (en) 2021-12-23
AU2021290733A1 (en) 2023-02-23
EP4169920A4 (en) 2024-08-07
JP2023532217A (ja) 2023-07-27

Similar Documents

Publication Publication Date Title
US7683062B2 (en) Crystalline form
JP6317320B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
AU2016253550B2 (en) A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2- carboxamide hydrochloride monohydrate
TW200911781A (en) Novel crystalline forms of a VEGF-R inhibitor
CN111777595A (zh) 一种环己烷甲酰胺类化合物的新晶型及其制备方法
WO2017152707A1 (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
CN115698007A (zh) 一种shp2抑制剂的晶型及其组合物、制备方法和用途
EP3315493B1 (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
WO2008111092A1 (en) Crystalline temozolomide monohydrate and process for preparation thereof
WO2021104257A1 (zh) 一种乙酰胆碱酯酶抑制剂的晶型及其制备方法和应用
JP2022519081A (ja) ロガラチニブ塩酸塩の一水和物およびその固体状態
EP3941472B1 (en) Crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
CN116528872A (zh) 5-氟-1-(4-氟-3-(4-(嘧啶-2-基)哌嗪-1-羰基)苄基)喹唑啉-2,4(1h,3h)-二酮的结晶形式及其制备
CN114349809A (zh) β-烟酰胺单核苷酸的晶型A及其制备方法
CN112830930B (zh) Eoc317的晶型及其制备方法与应用
WO2024214044A1 (en) Multicomponent complexes, including salts and hydrates and solvates, of inupadenant
TW202515572A (zh) 一種嘧啶苯胺類化合物的晶型、製備方法及應用
WO2009009292A2 (en) Crystalline forms of naltrexone methobromide
MX2008002987A (en) Novel crystalline form of a pyridazino [4 , 5-b]indole derivative
HK1183034B (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination